Twist Bioscience Corp (TWST): Long-Term Debt to Capital Ratio

Symbol and logo of brand Twist Bioscience Corp (TWST)

The price action of Twist Bioscience (TWST) reflects the development of a company that automates the creation of DNA sequences using AI-driven robots. The business is based on leadership in synthetic biology, offering affordable gene synthesis to the agro and biotech sectors. Thanks to silicon printing technologies, the firm has become a key link for laboratories, and the individual long-term debt-to-equity ratio stands at 0.18.

Long-Term Debt to Equity Ratio: twistbioscience.com (TWST) for 07/04/2022 - 10/28/2026

Financial and market metric breakdowns for Twist Bioscience (TWST)

- price and consensus price forecast:
Share Price Twist Bioscience Inc|TWST - Price Target Chart
- market capitalization data:
Market Capitalization Twist Bioscience, Inc.|TWST - Enterprise Value
- book capitalization data:
Book Value per Share Twist Bioscience|TWST - Company Net Assets|Market Cap to Book Value Multiple twistbioscience.com|TWST - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Twist Bioscience|TWST - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient twistbioscience.com|TWST - Company Debts|Debts to Net Assets Twist Bioscience, Inc.|TWST - Company Long-Term Liabilities|Amount of Current Liabilities Twist Bioscience
Fundamental valuation:TWST Twist Bioscience Inc
Core merchandise of Twist Bioscience, Inc.

Diversified DNA synthesis on silicon platforms minimizes industry risks for Twist Bioscience (TWST), yet long-term debt load on capital allows for an assessment of this strategy's resilience through the ratio of liabilities exceeding one year to equity. Analysis of this metric reveals the actual dependence of business development on borrowed resources, confirming the company's ability to finance expansion without threatening its financial independence or degrading shareholder value.

Main competitors

Long-Term Debt to Capital Ratio TEM|Long-Term Debt to Equity Qiagen Group QGEN|Long-Term Debt to Capital Ratio Isis Pharmaceuticals (IONS)|Long-Term Debt to Capital RGEN (Repligen Corporation)|RNA - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio CRISPR Therapeutics CRSP|GeneDx Holdings (WGS) - Long-Term Loans to Capital Ratio|RARE (Ultragenyx Pharma) - Long-Term Debt to Equity Ratio|Beam Tx (BEAM) - Long-Term Debt to Equity Ratio|SRPT: Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital TXG|NTLA (Intellia Therapeutics, Inc.) - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital Stoke Therapeutics Inc STOK|Long-Term Debt to Equity Ratio BioLife Corp (BLFS)|WVE - Long-Term Loans to Capital Ratio|Long-Term Debt to Equity Ratio Maze Therapeutics Inc (MAZE)|SION - Long-Term Debt to Capital Coefficient|Prime Medicine (PRME) - Long-Term Debt to Capital|Taysha Gene Therapies Inc (TSHA) - Long-Term Debt to Equity|QURE: Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital MGTX|REGENXBIO Inc. - Long-Term Debt to Equity|Long-Term Liabilities to Capital SLDB (solidbio.com)|Long-Term Debt to Equity OCGN|Ratio of Long-Term Indebtedness to Capital Pacific Biosciences of California, Inc. PACB|BNTC: Long-Term Debt to Capital|DSGN - Long-Term Debt to Equity Ratio|Rocket Pharmaceuticals - Long-Term Debt to Capital|4dmoleculartherapeutics.com (FDMT) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Capital LXEO (Lexeo Therapeutics Inc.)|Long-Term Liabilities to Capital KRRO|Long-Term Debt to Equity Editas EDIT|Long-Term Debt to Capital Ratio Silence Therapeutics Corp (SLN)|ProQR Therapeutics - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Codexis Inc CDXS|SGMO (Sangamo Therapeutics, Inc.) - Long-Term Debt to Capital|Nautilus Biotechnology (NAUT) - Long-Term Liabilities to Capital|MGX - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio Precision BioSciences Inc.|Long-Term Debt to Equity Ratio GBIO|Long-Term Debt to Equity Ratio BOLD|XCUR (Exicure, Inc.) - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital imunon.com IMNN|Long-Term Debt to Equity Ratio Phio Pharmaceuticals Corp. (PHIO)|Long-Term Loans to Capital Ratio Mustang Bio Inc MBIO|TransCode (RNAZ) - Long-Term Debt to Capital|BNGO: Long-Term Debt to Capital Ratio|Long-Term Debt to Equity Applied DNA Sciences, Inc.|bluebird bio Inc. (BLUE) - Long-Term Debt to Capital Ratio|IPA (ImmunoPrecise Antibodies Ltd) - Long-Term Debt to Capital|Long-Term Debt to Capital Omega Therapeutics Corp (OMGA)|Long-Term Debt to Equity Ratio Singular Genomics Systems|Long-Term Loans to Capital Ratio regulusrx.com RGLS|Syros Pharmaceuticals, Inc. - Long-Term Debt to Equity Ratio|Long-Term Debt to Equity Ratio Telesis Bio Inc. TBIO|Long-Term Debt to Capital TCON (TRACON)|UBX: Ratio of Long-Term Indebtedness to Capital